Xeris Pharmaceuticals Inc. (XERS) Tops Q3 EPS by 1c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $48.32 million versus the consensus estimate of $40.64 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• JPMorgan Upgrades PT Perusahaan Gas Negara Tbk (PGAS:JK) (PPAAF) to Overweight
• Darden Restaurants (DRI) Tops Q4 EPS by 3c, Misses on Revenue; Offers FY27 Guidance